无容量
医学
肿瘤科
内科学
头颈部癌
紫杉醇
随机对照试验
荟萃分析
癌症
免疫疗法
作者
Lingrong Tang,Tingting Liu,Jun Chen,Jun Dang,Guang Li
出处
期刊:Immunotherapy
[Future Medicine]
日期:2021-04-01
卷期号:13 (6): 541-555
被引量:1
标识
DOI:10.2217/imt-2020-0070
摘要
Aim: We assessed the efficiency of immune checkpoint inhibitors relative to other systemic therapies in previously treated recurrent/metastatic head and neck cancer. Materials & methods: Relative treatment effects were assessed from eligible randomized controlled trials using Bayesian network meta-analyses. Results: Among 15 trials evaluating 14 treatments, nivolumab achieved the best overall survival (OS) benefit; zalutumumab and buparlisib + paclitaxel provided the best progression-free survival benefit and objective response rate. Buparlisib + paclitaxel and zalutumumab were associated with the best OS rate at 6 and 12 months, respectively; nivolumab yielded the best OS rate at 18-24 months. Conclusion: Nivolumab was the most favorable treatment. Zalutumumab and buparlisib + paclitaxel had better efficiency, and might be a better selection for patients with programmed death-ligand 1-low/negative tumors than other treatments.
科研通智能强力驱动
Strongly Powered by AbleSci AI